Downloaded 19 times
Uploaded byGroup Health Cooperative
Barriers to opioid monitoring in primary care
This document summarizes barriers to opioid monitoring in primary care as presented by Dr. Erin Krebs. Some key barriers include short appointment times that limit monitoring, an assumption that opioids are effective without formally assessing benefits, overconfidence in risk perceptions, and negative attitudes viewing monitoring as "policing" rather than patient care. Implications discussed are formally assessing opioid benefits, addressing expectations and readiness to change, maintaining focus on medication harms rather than patient trustworthiness, and developing systems to support recommended monitoring practices.
More Related Content
Barriers to opioid monitoring in primary care
- 1. Barriers to OpioidMonitoring in Primary Care Erin E. Krebs, MD, MPH Minneapolis VA Health Care System University of Minnesota Medical School
- 2. Disclosures I have no financial relationships that may pose a conflict of interest to disclose I will not discuss off-label use of drugs, biologics or medical devices My work is supported by the VA. The views in this presentation are mine and do not necessarily reflect the position or policy of the VA or the US government
- 3. Outline Background—goals and current practice Specific barriers Implications for practice
- 4. Opioid monitoring Ongoing assessment of benefits/harms of treatment and adherence to therapy Primary goal is patient centered – to maximize benefit, minimize harm for individual patient Secondary goal is for public health – to minimize potential harm to others Tools: regularly scheduled visits, history-taking, care plans, outcome measures, drug testing, pill counts, prescription drug monitoring programs, tracking/documentation of aberrant behaviors
- 5. Balancing benefits andharms Pain Abuse/ relief addiction
- 6. Balancing benefits andharms Symptoms Dependence Social Mood Tolerance Abuse/ role Pain relief Uncertain Uncertain addiction Work benefits risks Injuries Hypogonadis Physica m Sleep l disorders activity Pain hyper- sensitivity
- 7. Limitations of monitoring ―Although evidence is limited, the expert panel concluded that chronic opioid therapy can be an effective therapy for carefully selected and monitored patients with chronic noncancer pain.‖ Chou et al., Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain. J Pain 2009;10(2):113-130
- 8. Limitations of monitoring ―Although evidence is limited, the expert panel concluded that chronic opioid therapy can be an effective therapy for carefully selected and monitored patients with chronic noncancer pain.‖ Most evidence for benefits of opioid monitoring strategies is low quality or indirect Chou et al., Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain. J Pain 2009;10(2):113-130
- 9. Limitations of monitoring ―Although evidence is limited, the expert panel concluded that chronic opioid therapy can be an effective therapy for carefully selected and monitored patients with chronic noncancer pain.‖ Most evidence for benefits of opioid monitoring strategies is low quality or indirect Monitoring doesn’t correct for lack of careful patient selection Doesn’t address underlying deficiencies in pain management training and services Chou et al., Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain. J Pain 2009;10(2):113-130
- 10. Opioid monitoring inpractice Studies show low use of opioid monitoring Evidence of risk stratification is mixed High risk patients receive more recommended practices Urine drug testing Mental health visits Documentation of adherence assessment But high risk patients also receive more high risk practices Early refills High opioid doses Concurrent benzodiazepines Krebs EK, Pain Med 2011;12: 740–746; Morasco BJ, J Gen Intern Med 2011;26:965–71; Seal KH, JAMA. 2012;307(9):940-947; Starrels JL, J Gen Intern Med 2011; 26(9):958–64
- 11. Opioid monitoring inpractice Primary care providers rarely follow recommendations for monitoring of opioid effectiveness, harms, and adherence Why?
- 12. ―The biggest problemin the whole thing is lack of time. Typically these are complex people with multiple problems, and you really could spend the whole appointment, more than one whole appointment just talking about this. We have all these reminders that we have to do, and all the scripts, and they’re wanting a podiatry consult, and an eye consult, and you just have to really sit down and go through a person’s record, and try to make a rational decision. It’s a horrible time problem. But I take it very seriously... What if you do create an opiate problem for somebody?‖
- 13. Structure of primarycare practice Short appointment times (15-20 minutes) Infrequent visits Heavy burden of non-reimbursed tasks Competing demands Complexity of visits and number of clinical tasks per visit increasing faster than visit duration Estimated time to accomplish all recommended preventive services: 7.4 hours/day One study found patients on chronic opioids received fewer cancer screenings Abbo ED, J Gen Intern Med 23(12):2058–65; Buckley DI, Ann Fam Med 2010;8:237-244. Chen MA, J Gen Intern Med 2010;26:58–63; Dyrbye LN, Arch Intern Med epub 2012; Yarnall KS, Am J Public Health
- 14. ―For those patientsthat have a legitimate reason for wanting to take it and if I can trust them—that they are not selling, they’re not abusing—and most of these are older patients of mine, I don’t have them sign a contract because they never request early refills, they don’t go to the ER in between visits to get them, and so there’s no need for me to do periodic drug screenings and so forth.‖
- 15. Confidence in riskperceptions Many physicians do not monitor adherence when patients are perceived as low risk Commonly cited factors: older age, verifiable source of pain, absence of red flags, ―gestalt‖ Research does not support this selective monitoring Neither patient report nor physician impression accurately identifies illicit substance use Physicians do not accurately perceive opioid misuse Presence of aberrant behaviors does not discriminate between patients with and without rx drug use disorder Good news : Many patients support universal monitoring, often based on personal experiences and concerns Fishbain DA, Clin J Pain 1999; 15:184-91; Fleming MF, J Pain, 2007;8:573-82; Melzer EC, Pain Med epub 2012; Vijayaraghavan M, J Gen Intern Med 2011;26:412–8.
- 16. ―I think it’sdestructive to a basic patient-doctor relationship. You’re there to help them and they can tell you their deepest, darkest secrets, but yet you’re policing them.‖
- 17. Negative attitudes aboutmonitoring Many physicians described opioid monitoring as being more like policing than doctoring Focus on trustworthiness of patient Conflict with patient-centered care Good news: Most patients did not view opioid monitoring this way Patients viewed opioids as dangerous drugs (causing addiction, interacting with other substances) Patients wanted physicians to focus on their safety
- 18. ―I usually don'thave to ask them if their pain is under good control. Most of them will come to me with their concerns.‖
- 19. A quick poll Please take a moment to think of the last patient for whom you wrote an opioid renewal prescription… How confident are you the patient is experiencing substantial benefit that is clearly outweighing adverse effects? Highly confident Somewhat confident Not at all confident
- 20. Assumption of effectiveness Several patients, but no physicians, mentioned lack of effectiveness as a reason to discontinue opioids Discontinuations/tapers were initiated by patients Some patients continued opioids without benefit Reasons: doctor’s advice, belief they would be worse off without it (supported by experience with brief withdrawals), belief that higher dose/stronger medicine was needed Assessing benefit is harder than it sounds, but is the most important task of opioid monitoring In the absence of benefit, no risk is acceptable
- 21. Cycle of ineffectiveopioid use Persistent pain/distress Unmet Help-seeking expectations +/- physical dependence Physician response Opioid
- 22. Cycle of ineffectiveopioid use Persistent pain/distress Unmet Help-seeking expectations +/- physical dependence Physician response Opioid
- 23. Cycle of ineffectiveopioid use Persistent pain/distress Unmet Help-seeking expectations +/- physical dependence Physician response Opioid
- 24. Cycle of ineffectiveopioid use Persistent pain/distress Unmet Help-seeking expectations +/- physical dependence Physician response Opioid
- 25. Cycle of ineffectiveopioid use Persistent pain/distress Unmet Help-seeking expectations +/- physical dependence Physician response Opioid
- 26. Interrupting the cycle Persistent pain/distress Unmet Help-seeking expectations +/- physical dependence Physician response Opioid
- 27. Implications for practice Assumption of effectiveness Patients starting opioids See principles Patients on established long-term opioid therapy Ask about pain, invest time in listening Assess opioid expectations, concerns, and experiences Provide education on evolving opioid evidence Address readiness for change at each visit
- 28. Implications for practice Negative attitudes about monitoring Maintain focus on benefits and harms of medication, rather than trustworthiness of patient Consider broad differential diagnosis for aberrant behaviors Read and recommend: Nicolaidis C. Pain Med 2011; 12: 890–897
- 29. Implications for practice Confidence in risk perceptions Train entire care team about harms Educate patients about harms Make it easier to do the right thing (see below) Structure of primary care Develop systems Institute clinic and facility-level protocols
- 30.
Editor's Notes
- #6 An oversimplified view of benefits and harms that is commonly presented
- #7 A more reality-based depiction of benefits and harms.
- #8 This is a summary statement from the APS/AAPM guidelines. I’d like to draw attention to a couple of points:-evidence is limited. -careful pt selection. Pts with conditions that are unlikely to respond, with high risk of harm, without established longitudinal relationshipOpioid monitoring doesn’t address underlying deficiencies… Not a substitute for comprehensive pain management plan. Many frustrations with opioid prescribing may result from relying too heavily on opioids
- #9 This is a summary statement from the APS/AAPM guidelines. I’d like to draw attention to a couple of points:-evidence is limited. -careful pt selection. Pts with conditions that are unlikely to respond, with high risk of harm, without established longitudinal relationshipOpioid monitoring doesn’t address underlying deficiencies… Not a substitute for comprehensive pain management plan. Many frustrations with opioid prescribing may result from relying too heavily on opioids
- #10 This is a summary statement from the APS/AAPM guidelines. I’d like to draw attention to a couple of points:-evidence is limited. -careful pt selection. Pts with conditions that are unlikely to respond, with high risk of harm, without established longitudinal relationshipOpioid monitoring doesn’t address underlying deficiencies… Not a substitute for comprehensive pain management plan. Many frustrations with opioid prescribing may result from relying too heavily on opioids
- #12 We know it isn’t because they are unconcerned about opioid prescribing—many surveys have shown that PCPs are concerned about opioid prescribing and often uncomfortable with it. I don’t believe it is due to lack of awareness of guidelines either—opioid monitoring is a complex task, so simple reminders, incentives, or guideline dissemination are unlikely to be effective. I’m going to focus on four key barriers to improved opioid monitoring—this isn’t a comprehensive review of all barriers, but a discussion of several I think are particularly relevant based on literature, my research, and my own experience as a primary care physician. To illustrate the barriers, I’ll present you with some physician quotes from semistructured interviews on this topic.
- #13 This physician was specifically reacting to the one page model opioid agreement from VA guidelines.
- #14 Singing to the choir… but these factors are not evident to many well meaning experts and policy makers.
- #15 This represents a common sentiment among physicians in our interviews. Only a few disagreed—saying it was impossible to tell who would have trouble.
- #16 Neither patient report nor physician impression accurately identify illicit substance use—studies comparing patient and physician report to drug testingPhysicians do not accurately perceive opioid misuse—study comparing physician impression with patient report of misuseAberrant drug related behaviors do not discriminate between patients with and without rx drug use disorder—ADRB can be associated with many factors (dysfunctional coping, social chaos, etc); PDUD can occur without ADRB
- #17 This physician is talking about drug testing.
- #19 We asked “how do you define a good response to opioid therapy?” A striking finding was that few actively assessed effectiveness and several stated that they assumed a lack of complaints indicated that the opioids were working. This is important considering that only a minority of patients with chronic pain can be expected have a significant clinical response to opioids while most with long term use will develop physical dependence. Many patients also had a hard time describing specific benefits of therapy.
- #20 We don’t have much existing literature on this issue, so I’m going to quickly survey those of you in the audience who prescribe opioids in primary care.I’m not asking this to judge your practice, but to illustrate that assessing effectiveness of opioid therapy is harder than it sounds, even for us, in this relatively expert group. Now another question, but I won’t ask for hands. If you are not confident that benefit is outweighing risk, are you discontinuing the medication?
- #26 Steady state where opioids are continued without discussion or reevaluation. Pt resigned to poor pain control, but believing she would be worse off without them and physician resigned to continuing opioids but not feeling too bad about it as long as patient isn’t requesting early refills or dose escalations.
- #27 Key points to intervene are when starting opioid therapy and when monitoring response and re-evaluating therapy